-
1.发明申请
公开(公告)号：WO2006074330A2
公开(公告)日：2006-07-13
申请号：PCT/US2006/000402
申请日：2006-01-05
Applicant: ABBOTT LABORATORIES , ROHDE, Jeffrey, J. , SHUAI, Qi , LINK, James, T. , PATEL, Jyoti, R. , DINGES, Jurgen , SORENSEN, Bryan, K. , YONG, Hong
Inventor： ROHDE, Jeffrey, J. , SHUAI, Qi , LINK, James, T. , PATEL, Jyoti, R. , DINGES, Jurgen , SORENSEN, Bryan, K. , YONG, Hong
IPC: C07C233/63 , C07D213/56 , C07D231/12 , C07D261/08 , C07D333/24 , A61K31/165 , A61K31/4409 , A61K31/381 , A61K31/415 , A61K31/42 , A61P3/04 , A61P3/10
CPC classification number: C07D207/277 , C07C233/11 , C07C233/52 , C07C233/58 , C07C233/63 , C07C237/24 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2603/74 , C07D211/78 , C07D213/56 , C07D231/12 , C07D261/08 , C07D333/24
Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶的抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。
-
公开(公告)号：WO2008154241A1
公开(公告)日：2008-12-18
申请号：PCT/US2008/065727
申请日：2008-06-04
Applicant: ABBOTT LABORATORIES , AKRITOPOULOU-ZANZE, Irini , WAKEFIELD, Brian D , MACK, Helmut , TURNER, Sean C , GASIECKI, Alan F , GRACIAS, Vijaya J , SARRIS, Kathy , KALVIN, Douglas M , MICHMERHUIZEN, Melissa J , SHUAI, Qi , PATEL, Jyoti R , BAKKER, Margaretha , TEUSCH, Nicole , JOHNSON, Eric T , KOVAR, Peter J , DJURIC, Stevan W , LONG, Andrew J , VASUDEVAN, Anil , HOBSON, Adrian , ST. JOHN MOORE, Nigel , WANG, Lu , GEORGE, Dawn , LI, Biqin , FRANK, Kristine
Inventor： AKRITOPOULOU-ZANZE, Irini , WAKEFIELD, Brian D , MACK, Helmut , TURNER, Sean C , GASIECKI, Alan F , GRACIAS, Vijaya J , SARRIS, Kathy , KALVIN, Douglas M , MICHMERHUIZEN, Melissa J , SHUAI, Qi , PATEL, Jyoti R , BAKKER, Margaretha , TEUSCH, Nicole , JOHNSON, Eric T , KOVAR, Peter J , DJURIC, Stevan W , LONG, Andrew J , VASUDEVAN, Anil , HOBSON, Adrian , ST. JOHN MOORE, Nigel , WANG, Lu , GEORGE, Dawn , LI, Biqin , FRANK, Kristine
IPC: C07D403/04 , C07D413/04 , C07D417/04
CPC classification number: C07D403/04 , C07D413/04 , C07D417/04
Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R 1 , R 2 , R 3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.
Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，其中A，R 1，R 2，R 3和m在说明书中定义。 本发明还涉及制备所述化合物的方法和含有所述化合物的组合物，其可用于抑制激酶如糖原合酶激酶3（GSK-3），Rho激酶（ROCK），Janus激酶（JAK），AKT，PAK4 ，PLK，CK2，KDR，MK2，JNK1，极光，pim1和nek2。
-
3.发明申请ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME 审中-公开作为11-羟基脱氢酶脱氢酶1型酶的抑制剂的酰胺 - 乙酰胺衍生物
公开(公告)号：WO2005108368A1
公开(公告)日：2005-11-17
申请号：PCT/US2005/015304
申请日：2005-04-29
Applicant: ABBOTT LABORATORIES , LINK, James, T. , PLIUSHCHEV, Marina, A. , ROHDE, Jeffrey, J. , WODKA, Dariusz , PATEL, Jyoti, R. , SHUAI, Qi
Inventor： LINK, James, T. , PLIUSHCHEV, Marina, A. , ROHDE, Jeffrey, J. , WODKA, Dariusz , PATEL, Jyoti, R. , SHUAI, Qi
IPC: C07D213/06
CPC classification number: C07D213/06 , C07C237/04 , C07C237/24 , C07C2601/02 , C07C2603/74 , C07D207/02 , C07D209/08 , C07D213/24 , C07D213/72 , C07D213/74 , C07D213/85 , C07D223/16 , C07D253/06 , C07D257/04 , C07D277/64 , C07D295/15 , C07D295/185 , C07D471/08 , C07D491/04
Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.
Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征以及其它疾病和病症的用途 由过度的糖皮质激素作用介导。
-
公开(公告)号：WO2009026422A3
公开(公告)日：2009-02-26
申请号：PCT/US2008/073830
申请日：2008-08-21
Applicant: ABBOTT LABORATORIES , BITNER, R., Scott , BROWMAN, Kaitlin, E , BRUNE, Michael, E , CHEN, Yixian , DINGES, Jurgen , DRESCHER, Karla , JACOBSON, Peer , JAE, Hwan-soo , KURUKULASURIYA, Ravi , LINK, James, T. , MADAR, David, J. , PATEL, Jyoti, R. , PLIUSHCHEV, Marina, A. , ROHDE, Jeffrey, J. , RUETER, Lynne, E. , SHUAI, Qi , SORENSEN, Bryan, K. , WANG, Jiahong , WICKE, Karsten, M. , WINN, Martin , WODKA, Dariusz , YEH, Vince , YONG, Hong
Inventor： BITNER, R., Scott , BROWMAN, Kaitlin, E , BRUNE, Michael, E , CHEN, Yixian , DINGES, Jurgen , DRESCHER, Karla , JACOBSON, Peer , JAE, Hwan-soo , KURUKULASURIYA, Ravi , LINK, James, T. , MADAR, David, J. , PATEL, Jyoti, R. , PLIUSHCHEV, Marina, A. , ROHDE, Jeffrey, J. , RUETER, Lynne, E. , SHUAI, Qi , SORENSEN, Bryan, K. , WANG, Jiahong , WICKE, Karsten, M. , WINN, Martin , WODKA, Dariusz , YEH, Vince , YONG, Hong
IPC: A61K31/495 , A61K31/445 , C07C233/23 , C07D471/02
Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.
-
5.发明申请
公开(公告)号：WO2006074244A2
公开(公告)日：2006-07-13
申请号：PCT/US2006/000210
申请日：2006-01-05
Applicant: ABBOTT LABORATORIES , PATEL, Jyoti, R. , SHUAI, Qi , LINK, James, T. , ROHDE, Jeffrey, J. , DINGES, Jurgen , SORENSEN, Bryan, K. , WINN, Martin , YONG, Hong , YEH, Vince, S.
Inventor： PATEL, Jyoti, R. , SHUAI, Qi , LINK, James, T. , ROHDE, Jeffrey, J. , DINGES, Jurgen , SORENSEN, Bryan, K. , WINN, Martin , YONG, Hong , YEH, Vince, S.
IPC: C07C235/14 , C07C317/16 , C07C323/41 , C07D257/04 , C07D233/54 , C07D261/08 , C07D213/64 , C07D207/48 , A61K31/4402 , A61P3/10
CPC classification number: C07C233/23 , C07C235/14 , C07C237/24 , C07C255/31 , C07C255/47 , C07C259/16 , C07C311/08 , C07C311/29 , C07C311/46 , C07C311/51 , C07C317/22 , C07C317/30 , C07C317/44 , C07C323/41 , C07C323/60 , C07C2601/04 , C07C2601/14 , C07C2601/18 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D207/48 , C07D213/64 , C07D233/64 , C07D257/04 , C07D261/08
Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。
-
Patent Agency Ranking6.发明公开ADAMANTYL DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME 有权ADAMANTYL-DERIVATE ALS INHIBITOREN DES 11-BETA-HYDOXOSTEROID-DEHYDROGENASE-1-ENZYMS
公开(公告)号：EP1846363A2
公开(公告)日：2007-10-24
申请号：EP06717418.5
申请日：2006-01-05
Applicant: ABBOTT LABORATORIES
Inventor： PATEL, Jyoti, R. , SHUAI, Qi , LINK, James, T. , ROHDE, Jeffrey, J. , DINGES, Jurgen , SORENSEN, Bryan, K. , WINN, Martin , YONG, Hong , YEH, Vince, S.
IPC: C07C235/14 , C07C317/16 , C07C323/41 , C07D257/04 , C07D233/54 , C07D261/08 , C07D213/64 , C07D207/48 , A61K31/4402 , A61P3/10
CPC classification number: C07C233/23 , C07C235/14 , C07C237/24 , C07C255/31 , C07C255/47 , C07C259/16 , C07C311/08 , C07C311/29 , C07C311/46 , C07C311/51 , C07C317/22 , C07C317/30 , C07C317/44 , C07C323/41 , C07C323/60 , C07C2601/04 , C07C2601/14 , C07C2601/18 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D207/48 , C07D213/64 , C07D233/64 , C07D257/04 , C07D261/08
Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。
-
7.发明公开
公开(公告)号：EP1846362A2
公开(公告)日：2007-10-24
申请号：EP06717579.4
申请日：2006-01-05
Applicant: ABBOTT LABORATORIES
Inventor： ROHDE, Jeffrey, J. , SHUAI, Qi , LINK, James, T. , PATEL, Jyoti, R. , DINGES, Jurgen , SORENSEN, Bryan, K. , YONG, Hong , KURUKULASURIYA, Ravi , YEH, Vince
IPC: C07C233/63 , C07D213/56 , C07D231/12 , C07D261/08 , C07D333/24 , A61K31/165 , A61K31/4409 , A61K31/381 , A61K31/415 , A61K31/42 , A61P3/04 , A61P3/10
CPC classification number: C07D207/277 , C07C233/11 , C07C233/52 , C07C233/58 , C07C233/63 , C07C237/24 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2603/74 , C07D211/78 , C07D213/56 , C07D231/12 , C07D261/08 , C07D333/24
Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶的抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。
-
8.发明授权ADAMANTYL DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME 有权金刚衍生物作为11-β羟类固醇脱氢酶-1酶抑制剂
公开(公告)号：EP1846363B1
公开(公告)日：2012-04-25
申请号：EP06717418.5
申请日：2006-01-05
Applicant: Abbott Laboratories
Inventor： PATEL, Jyoti, R. , SHUAI, Qi , LINK, James, T. , ROHDE, Jeffrey, J. , DINGES, Jurgen , SORENSEN, Bryan, K. , WINN, Martin , YONG, Hong , YEH, Vince, S.
IPC: C07C235/14 , C07C317/16 , C07C323/41 , C07D257/04 , C07D233/54 , C07D261/08 , C07D213/64 , C07D207/48 , A61K31/4402 , A61P3/10
CPC classification number: C07C233/23 , C07C235/14 , C07C237/24 , C07C255/31 , C07C255/47 , C07C259/16 , C07C311/08 , C07C311/29 , C07C311/46 , C07C311/51 , C07C317/22 , C07C317/30 , C07C317/44 , C07C323/41 , C07C323/60 , C07C2601/04 , C07C2601/14 , C07C2601/18 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D207/48 , C07D213/64 , C07D233/64 , C07D257/04 , C07D261/08
Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
-
公开(公告)号：EP2167491A1
公开(公告)日：2010-03-31
申请号：EP08770094.4
申请日：2008-06-04
Applicant: Abbott Laboratories , Abbott GmbH & Co. KG
Inventor： AKRITOPOULOU-ZANZE, Irini , WAKEFIELD, Brian D , MACK, Helmut , TURNER, Sean C , GASIECKI, Alan F , GRACIAS, Vijaya J , SARRIS, Kathy , KALVIN, Douglas M , MICHMERHUIZEN, Melissa J , SHUAI, Qi , PATEL, Jyoti R , BAKKER, Margaretha , TEUSCH, Nicole , JOHNSON, Eric F. , KOVAR, Peter J , DJURIC, Stevan W , LONG, Andrew J , VASUDEVAN, Anil , HOBSON, Adrian , ST. JOHN MOORE, Nigel , WANG, Lu , GEORGE, Dawn , LI, Biqin , FRANK, Kristine
IPC: C07D403/04 , C07D413/04 , C07D417/04
CPC classification number: C07D403/04 , C07D413/04 , C07D417/04
Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.
-
10.发明公开ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME 有权ADAMANTYLACETAMIDDERIVATE ALS INHIBITOREN DES 11-BETA-HYDOXOSTEROIDDEHYDROGENASE-TYP-1-ENZYMS
公开(公告)号：EP1751108A1
公开(公告)日：2007-02-14
申请号：EP05742013.5
申请日：2005-04-29
Applicant: ABBOTT LABORATORIES
Inventor： LINK, James T. , PLIUSHCHEV, Marina A. , ROHDE, Jeffrey J. , WODKA, Dariusz , PATEL, Jyoti R. , SHUAI, Qi
IPC: C07D213/06 , C07D213/24 , C07D213/72 , C07D207/02 , A61K31/44 , A61K31/445
CPC classification number: C07D213/06 , C07C237/04 , C07C237/24 , C07C2601/02 , C07C2603/74 , C07D207/02 , C07D209/08 , C07D213/24 , C07D213/72 , C07D213/74 , C07D213/85 , C07D223/16 , C07D253/06 , C07D257/04 , C07D277/64 , C07D295/15 , C07D295/185 , C07D471/08 , C07D491/04
Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.
Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖，脂质障碍，代谢综合征以及其它疾病和病症的用途 由过度的糖皮质激素作用介导。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.039 seconds)
